[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results].
M H
MH
Reijers
G J
GJ
Weverling
S
S
Jurriaans
F W
FW
Wit
R
R
van Leeuwen
S M
SM
Bruisten
P H
PH
Frissen
H M
HM
Weigel
J W
JW
Mulder
R W
RW
ten Kate
F
F
de Wolf
H
H
Schuitemaker
J M
JM
Lange
D000998:Antiviral Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D019888:Nelfinavir / Q000008:administration & dosage*; D010865:Pilot Projects; D019258:Saquinavir / Q000008:administration & dosage*; D018119:Stavudine / Q000008:administration & dosage*; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D019259:Lamivudine; D018119:Stavudine; D019888:Nelfinavir; D019258:Saquinavir